PUBLISHER: The Insight Partners | PRODUCT CODE: 1494496
PUBLISHER: The Insight Partners | PRODUCT CODE: 1494496
The Europe vascular closure device market was valued at US$ 362.63 million in 2022 and is expected to reach US$ 621.74 million by 2030; it is estimated to record a CAGR of 7.0% from 2022 to 2030.
Strategic Activities by Manufacturers Drive Europe Vascular Closure Device Market
The medical device industry is developing significantly due to the increasing demand for technologically advanced products. Major market players engage in new product developments, launches, and approvals to ensure the innovation and development of efficient products. A few of the recent product launches and approvals in the vascular closure devices market are mentioned below.
In September 2022, Haemonetics Corporation obtained CE mark certification for its VASCADE and VASCADE MVP venous vascular closure systems. The CE marking allows Haemonetics to engage in the next steps of launching both products into the European Union (EU); it also allows the company to enter into other geographies that recognize CE marking. As of 2021, VASCADE MVP was the first and only FDA-approved vascular closure device indicated for use following atrial fibrillation (AF) ablation to allow same-day discharge.
In September 2023, a cross-seal, suture-mediated vascular closure device system by Terumo Medical Corporation received approval from the FDA. The device is indicated for the percutaneous delivery of sutures for closing a common femoral artery access site while reducing time-to-hemostasis in patients who have undergone diagnostic or interventional catheterization using 8F to 18F sheaths. The Cross-Seal System is indicated for one access site per leg. Such strategic initiatives are likely to emerge as a key trend in the Europe vascular closure device market during the forecast period.
Europe Vascular Closure Device Market Overview
Cardiovascular disorders are among the most common causes of death in Germany. Changing lifestyles among the masses is a major risk factor for this disease. Cardiovascular disorders account for ~40% of deaths in Germany, followed by cancer and diabetes. According to the WHO, the death toll due to coronary heart disease in Germany reached 147,055 (i.e., 20.98% of total mortalities) in 2020. The presence of developed healthcare facilities and the increasing number of minimally invasive cardiology procedures are among the factors that are likely to create demand for vascular closure devices. According to data published in the Burden of Stroke in Europe report prepared by King's College London for the Stroke Alliance for Europe, Germany records ~88,922 stroke cases annually, which is equivalent to nearly 52 cases per 100,000 inhabitants. The total prevalence of stroke in Germany was 526,774, which accounts for 338.5 strokes per 100,000 residents. Germany also has a significant mortality rate of stroke as it reports 75,861 deaths due to stroke per year. According to the Burden of Stroke in Europe report, stroke cases in Germany are likely to surge by 30% by 2035, while the prevalence of stroke is anticipated to rise to 19% by the end of 2035. Thus, the significantly growing incidence of stroke and cardiovascular disorder drives the vascular closure devices market growth in Germany.
Europe Vascular Closure Device Market Revenue and Forecast to 2030 (US$ Million)
Europe Vascular Closure Device Market Segmentation
The Europe vascular closure device market is segmented based on product type, access, procedure, end user, and country.
Based on product type, the Europe vascular closure device market is segmented into active approximators, passive approximators, and external hemostatic devices. The passive approximators segment held the largest share in 2022. The active approximators segment is further segmented into suture mediated device and staple clips mediated device. The passive approximators segment is further segmented into sealant and gel based, compression devices, and collagen plug.
By access, the Europe vascular closure device market is bifurcated into femoral access and radial access. The femoral access segment held a larger share in 2022.
By procedure, the Europe vascular closure device market is segmented into interventional cardiology, interventional radiology, and endovascular surgery. The interventional cardiology access segment held the largest share in 2022.
In terms of end user, the Europe vascular closure device market is categorized into hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest share in 2022.
Based on country, the Europe vascular closure device market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. The Rest of Europe dominated the Europe vascular closure device market in 2022.
Abbott Laboratories, Becton Dickinson and Co, Cardinal Health Inc, Cordis Corp, ENDOCOR GmbH & CO KG, Haemonetics Corp, Medtronic Plc, Teleflex Inc, and Vasorum Ltd are some of the leading companies operating in the Europe vascular closure device market.